Q-omics provides the consensus-scored ZNF862 profile across patient tissues and cancer cell-line models. ZNF862 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF862 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF862 RNA expression shows 19,940 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where ZNF862 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF862 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF862 survival associations across molecular data types. ZNF862 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF862 RNA expression–survival associations across cancer types. High ZNF862 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, UCS, PAAD and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF862 RNA expression.
This table summarizes ZNF862 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF862. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF862 shows lower tumor expression in THCA, UCEC, BRCA and HNSC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher ZNF862 RNA expression in normal versus tumor tissue (log2 FC = −1.174, t-test p < 0.001).
This table shows molecular features associated with ZNF862 in patient tissues and cancer cell lines. In patient samples, ZNF862 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF862 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
